TOPLINE

Among patients with overactive bladder who had previously received anticholinergics or mirabegron, nearly 70% reported consistent satisfaction with vibegron and many preferred it to their prior therapy. Nearly 60% continued treatment throughout the year, with improvements in symptoms and health-related quality of life (HRQOL).

METHODOLOGY

• Researchers conducted a phase 4, prospective observational study across 45 US study sites to evaluate satisfaction with vibegron, treatment persistence, and safety among patients with overactive bladder in a real-world US setting.
• A total of 403 patients (mean age, 56.1 years; 71.7% women) with overactive bladder were enrolled; patients had been previously treated with anticholinergics (n = 142) or mirabegron, with or without anticholinergics (n = 261).
• Patients received a prescription for vibegron 75 mg once daily and obtained the medication through the standard prescription process, with payments determined by their insurance plan. 
• Patients completed a questionnaire to measure how much bladder symptoms bothered them and how these symptoms affected their HRQOL at enrollment and each month over 12 months. 
• The primary outcome was satisfaction with the treatment, measured via the satisfaction domain of the Overactive Bladder Satisfaction With Treatment Questionnaire. Scores > 60 on a range of 0-100 indicated satisfaction.

TAKEAWAY

• At 12 months post-treatment, the satisfaction domain score was 65.6, and 69.0% of patients reported consistent satisfaction with vibegron.
• Of the patients who responded to the satisfaction questionnaire at 12 months, 77.9% preferred vibegron over their prior therapy.
• Treatment persistence at 12 months was observed in 59.8% of patients. Symptom severity scores fell by a mean of 26.9 points from baseline, whereas HRQOL scores increased by 24.5 points.
• At least one treatment-emergent adverse event occurred in 36.0% of patients; the most common events reported were urinary tract infection (4.0%), headache (2.7%), and dizziness (2.2%). Serious adverse events were reported in 2.0% of patients, and treatment discontinuation due to adverse events was noted in 7.9%. One death was reported and was deemed unrelated to vibegron.

IN PRACTICE

"These positive, real-world patient-reported outcomes also correspond with the favorable efficacy and safety results of completed phase 3 clinical trials and suggest that vibegron may be a beneficial treatment option for patients with OAB [overactive bladder]," the authors wrote.

SOURCE

The study was led by Michael J. Kennelly, MD, of the Atrium Health Wake Forest School of Medicine at the Carolinas Medical Center in Charlotte, North Carolina. It was published online on October 12, 2026, in Therapeutic Advances in Urology.

LIMITATIONS

The study did not involve randomization and lacked a control group, limiting comparisons between vibegron and other treatments for overactive bladder. The findings may not be applicable to patients with overactive bladder who are naive to treatment. The open-label design may have affected satisfaction ratings owing to patient awareness. 

DISCLOSURES

This study was funded by Sumitomo Pharma America, Inc. Some authors disclosed consulting relationships, grants or research funding, or advisory roles with multiple companies, including the study funding organization. One author was an employee of Sumitomo Pharma America, Inc., at the time the work was conducted, and two authors reported current employment with the company.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.